FDA clears in vivo gene editing therapy for trials in US
Drug Discovery World
MARCH 9, 2023
The post FDA clears in vivo gene editing therapy for trials in US appeared first on Drug Discovery World (DDW). The US Food and Drug Administration (FDA) has cleared Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).
Let's personalize your content